Products - Eye conditions | Topic | NICE

Showing 106 products

Date | Title

Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 October 2024
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 September 2024
Diabetic retinopathy: management and monitoring (NG242)
Product type:
Guidance
Programme:
NICE guideline
Published:
13 August 2024
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 May 2024
Published:
27 August 2008
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 May 2024
Published:
27 November 2013
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 May 2024
Published:
22 May 2013
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (TA960)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 March 2024
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2024
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) (TA941)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2023
Ranibizumab for treating diabetic macular oedema (TA274)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 October 2023
Published:
27 February 2013
Trabeculectomy with a biodegradable collagen matrix implant for glaucoma (IPG750)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
17 January 2023
Ab interno canaloplasty for open-angle glaucoma (IPG745)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 November 2022
YAG laser vitreolysis for symptomatic vitreous floaters (IPG741)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 October 2022
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 September 2022
Brolucizumab for treating diabetic macular oedema (TA820)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2022
Faricimab for treating diabetic macular oedema (TA799)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Faricimab for treating wet age-related macular degeneration (TA800)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Nerve graft for corneal denervation (IPG729)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
29 June 2022
Glaucoma: diagnosis and management (NG81)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
26 January 2022
Published:
1 November 2017
Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma (IPG692)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 April 2021
Brolucizumab for treating wet age-related macular degeneration (TA672)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 February 2021
Artificial iris insertion for acquired aniridia (IPG674)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 July 2020
Artificial iris insertion for congenital aniridia (IPG675)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 July 2020
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
9 October 2019
High-intensity focused ultrasound for glaucoma (IPG661)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 September 2019
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 July 2019
Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma (IPG612)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 April 2018
Age-related macular degeneration (NG82)
Product type:
Guidance
Programme:
NICE guideline
Published:
23 January 2018
Aflibercept for treating choroidal neovascularisation (TA486)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 November 2017
Cataracts in adults: management (NG77)
Product type:
Guidance
Programme:
NICE guideline
Published:
26 October 2017
Ab externo canaloplasty for primary open-angle glaucoma (IPG591)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
13 September 2017
Holoclar for treating limbal stem cell deficiency after eye burns (TA467)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 August 2017
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 July 2017
Trabecular stent bypass microsurgery for open-angle glaucoma (IPG575)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 February 2017
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Miniature lens system implantation for advanced age-related macular degeneration (IPG565)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 September 2016
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2015
Insertion of a subretinal prosthesis system for retinitis pigmentosa (IPG537)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 December 2015
Implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyes (IPG534)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 November 2015
Aflibercept for treating diabetic macular oedema (TA346)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Insertion of an epiretinal prosthesis for retinitis pigmentosa (IPG519)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 June 2015
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2014
Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia (IPG466)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 September 2013
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 July 2013
Corneal inlay implantation for correction of presbyopia (IPG455)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 April 2013
Epiretinal brachytherapy for wet age-related macular degeneration (IPG415)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 December 2011
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2011
Trabeculotomy ab interno for open angle glaucoma (IPG397)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 May 2011
Laser correction of refractive error following non-refractive ophthalmic surgery (IPG385)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 March 2011
Phototherapeutic laser keratectomy for corneal surface irregularities (IPG358)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 September 2010
Limited macular translocation for wet age-related macular degeneration (IPG339)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
19 May 2010
Macular translocation with 360° retinotomy for wet age-related macular degeneration (IPG340)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
19 May 2010
Arteriovenous crossing sheathotomy for branch retinal vein occlusion (IPG334)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 March 2010
Corneal endothelial transplantation (IPG304)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 June 2009
Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions) (IPG299)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 May 2009
Implantation of an opaque intraocular lens for intractable double vision (IPG293)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 March 2009
Intraocular lens insertion for correction of refractive error, with preservation of the natural lens (IPG289)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 February 2009
Implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery (IPG264)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 June 2008
Corneal implants for keratoconus (IPG227)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 July 2007
Corneal implants for the correction of refractive error (IPG225)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 July 2007
Tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium (IPG216)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 April 2007
Implantation of accommodating intraocular lenses for cataract (IPG209)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 February 2007
Photorefractive (laser) surgery for the correction of refractive errors (IPG164)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 March 2006
Retrobulbar irradiation for thyroid eye disease (IPG148)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
14 December 2005
Endoscopic dacryocystorhinostomy (IPG113)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2005
Scleral expansion surgery for presbyopia (IPG70)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 July 2004
Insertion of hydrogel keratoprosthesis (IPG69)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 June 2004
Transpupillary thermotherapy for age-related macular degeneration (IPG58)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 May 2004
Radiotherapy for age-related macular degeneration (IPG49)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 March 2004
AI technologies for detecting diabetic retinopathy (MIB265)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
6 July 2021
ORA G3 to measure corneal hysteresis (MIB150)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
18 June 2018
Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
24 April 2018
Boston Keratoprosthesis Type I for corneal blindness (MIB91)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
18 January 2017
Icare rebound tonometer to measure intraocular pressure (MIB57)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
15 March 2016
AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
15 December 2015
TearLab osmolarity system for diagnosing dry eye disease (MIB47)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
15 December 2015
LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
21 April 2015
The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma (MIB14)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
19 November 2014
Serious eye disorders (QS180)
Product type:
Quality standard
Published:
12 February 2019
Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 December 2024
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 April 2025
Teprotumumab for treating thyroid eye disease [ID6432]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Glaucoma - lerdelimumab (CAT-152) [ID383]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care
Status:
Awaiting development
Expected publication date:
TBC
Timrepigene emparvovec for treating choroideremia [ID3916]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Miniature lens system implantation for advanced age-related macular degeneration
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Ranibizumab port delivery system for treating diabetic macular oedema ID6137
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
High-dose aflibercept for treating wet age-related macular degeneration TS ID 10590
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aflibercept for untreated diabetic macular oedema TS ID 10621
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lateral orbital decompression
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pegcetacoplan for treating geographic atrophy [ID4041]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears TSID8472
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
NVK-002 for treating myopia in people 3 to 17 years TSID 11961
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
AI in retinal scanning MT524 (MIB265)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
Aflibercept for untreated retinopathy in babies born preterm TS ID 11943
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Polyhexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC